I just got this result after a year of Acalabrutinib and Venetoclax on the Majic trial.
I'm currently waiting for the clonoSEQ MRD6 results. Below are the FLOW test results. Are they comparable. If so, I have a long long way to go for MRD6.
Bone marrow, flow cytometric immunophenotyping:
1. A CD5-positive, kappa light chain-restricted B-cell population is detected. MRD = 0.39%.
2 A CD5-positive, light chain-indeterminate B-cell population is detected. MRD = 0.034%.
This note was attached to the results:
This CLL MRD assay is validated to a sensitivity level of 0.002%.
Previous therapy targeting cell surface antigen(s) can interfere with this assay's performance.
Is this significant?
Thanks
JDG45